Evinature’s CurQD® Protocol was shaped by years of inquiry into how the body supports gut balance and immune harmony. The formulation combines two botanicals — curcumin and Qing Dai (Indigo naturalis) — each studied for its interactions within the intestinal environment.
A central pathway associated with this combination is the aryl hydrocarbon receptor (AhR) — a receptor distributed along the gut lining that helps coordinate communication among the immune system, the intestinal barrier, and the microbiome. When engaged by certain plant-derived molecules, AhR has been observed to contribute to equilibrium across these systems, aligning with the body’s natural capacity for intestinal resilience.
Guided by this understanding, CurQD® was developed using a gut-directed strategy, helping the body re-establish balance — followed by structured long-term protocols intended to support ongoing stability over time. These are formulated for each individual through our online assessment.
This two-phase framework reflects the real-world needs of individuals managing long-term gut health: addressing short-term discomfort while aiming for lasting balance within the digestive system.
The studies below build on this scientific foundation, examining CurQD® through clinical research and real-world observation to better characterize safety, tolerability, and biological effects:
Initial Multicenter Study
A multicenter, real-world study across five academic centers — published in Alimentary Pharmacology & Therapeutics in 2023 and republished in the Journal of Crohn’s and Colitis in 2025 — evaluated the use of the CurQD® Protocols in adults with ongoing digestive challenges. The group included individuals with a wide range of previous care experiences.
Results
The study documented a wide range of observations related to participant experiences and measured study endpoints. These included numerical shifts in several tracked parameters such as participant-reported questionnaires and laboratory markers. For example, changes were recorded in SCCAI scores and fecal calprotectin levels across the study period, and the researchers also noted the overall safety profile reported by participants. These findings were presented by the study authors as part of their analysis of how individuals engaged with the protocol over time.
Takeaways
The published report described patterns that the investigators considered noteworthy, particularly in light of the diverse backgrounds of the participants and the fact that many had previously explored various supportive options. The authors highlighted that the data reflected participant experiences with a protocol built from botanical components and discussed this in the broader context of real world use.
Significance
In their discussion, the researchers emphasized that the study contributed to ongoing academic interest in botanical based approaches. They noted that the findings may help inform future work exploring where such protocols might fit within wider integrative models of digestive wellness and how individuals with different care histories engage with them. The study authors suggested that these results add to the growing conversation within the scientific community about complementary strategies that people may consider alongside their existing care plans.
ECCO Guidelines Inclusion
By 2025, CurQD was included in published materials that explore naturally sourced compounds as part of the broader discussion on digestive wellness. This highlights the increasing curiosity surrounding plant based approaches in professional settings
Harvard Medical Editorial
Clinical Gastroenterology and Hepatology published an editorial by Dr Ashwin Ananthakrishnan of Harvard Medical School in response to the 2023 CurQD® randomized controlled trial. The editorial discussed the design and academic relevance of the study and noted CurQD® as a topic of interest within scientific and professional discourse.
Bowel Urgency Improvement
A post-hoc analysis published in Journal of Crohn’s & Colitis examined data from the CurQD® randomized controlled trial in 2023 to evaluate its impact on bowel irregularity. Individuals treated with Evinature’s CurQD® Protocols showed a significant reduction in urgency, measured by the SCCAI score, compared to placebo. This urgency-focused analysis described CurQD®’s effects on a key quality-of-life indicator, complementing broader clinical endpoints.
First CurQD® Study Centered on a Specific Group of Participants
A multicenter observational project focused on adults living with long term digestive challenges was published in the Journal of Crohn’s & Colitis in January 2025, followed by Frontiers in Gastroenterology in July 2025. The study examined participants engaged with the CurQD® protocol as an added component to their existing care plans and included individuals with a wide range of prior care experiences, including those familiar with biologic methods.
Results
The publication presented a range of numerical observations gathered from participant assessments and laboratory markers during the study period. These included shifts in experience-based scoring tools, fecal calprotectin readings, and other recorded parameters. The report also included notes on participant experiences with ongoing use, along with the frequency and nature of minor side effects mentioned during follow up.
Takeaways
The publication described how participants in the study engaged with the CurQD® protocol and outlined various patterns that appeared over time. The group included many individuals with extensive prior treatment experience, which was highlighted as an important element of the cohort’s background when presenting the data.
Significance
As the first project focused specifically on this protocol within a broader digestive wellness context, the publication contributed to the expanding academic interest surrounding CurQD®. It also showed that exploration of this approach is now being examined across different areas of the digestive system, adding to ongoing discussions about integrative models of support.
Ultrasound-Based Study at University of Chicago
A retrospective study conducted at the University of Chicago and published in Journal of Crohn’s & Colitis in January 2025 assessed how adults engaged with the CurQD® protocol using intestinal ultrasound markers, marking the first time this imaging method was applied in research involving CurQD®
Results
The publication reported a series of numerical observations collected over an eight week period. These included shifts in participant-reported digestive scoring tools, fecal calprotectin values, and imaging based measurements. The report also presented comparisons between initial and follow up data to illustrate how these markers changed during the study timeframe.
Takeaways
The authors highlighted patterns in both participant reported experiences and the objective measurements gathered through ultrasound and laboratory testing. The use of intestinal ultrasound was noted as offering a visual way to track changes in the intestinal environment over the study period.
Significance
Conducted under the leadership of Dr David Rubin, this was the first United States based project to apply this specific imaging method to an evaluation of the CurQD® protocol. The publication added imaging focused observations to the broader academic discussion surrounding naturally derived compounds and their study in digestive health research
Prolonged Multicenter International Pediatric Study
A multicenter real-world study published in2024 in Frontiers in Pediatrics evaluated the safety and use of CurQD®, by Evinature, in children and adolescents described in the medical literature as living with long-term gut challenges, after engaging with prior medical routines. The study followed participants during both an induction and long-term health balance.
Results
During the induction phase, participants showed numerical shifts in clinical scoring tools, along with biomarker measurements such as fecal calprotectin. A high proportion — 91.7% — showed decreases in calprotectin values, and 58.3% reached levels categorized by the researchers as “normalized.”
Over the following months, two-thirds (67%) of those who continued the protocol maintained these trends or showed stable measurements.
Takeaways
The findings described CurQD®’s use in a pediatric population, including changes in measurement tools alongside objective biomarker patterns, with a safety profile reported as favorable.
Significance
This study broadened the evidence base supporting consideration of CurQD® for younger individuals — a group where options for digestive-health support can be limited.
International Multicenter Study
A multicenter, randomized, double-blind, placebo-controlled trial published in Clinical Gastroenterology and Hepatology in 2024 investigated the efficacy and safety of CurQD® in individuals with active gut issues. Conducted at leading medical centers in Greece and Israel, the study enrolled eighty-eight participants with diverse reported states and prior care histories.
Results
At eight weeks, the publication reported differences between groups based on clinical scoring categories. Reported figures included:
-
85.7% showing a notable shift in scoring categories
-
50% reaching clinician-defined low-activity ranges
-
75% showing endoscopic improvement
During a gut balance phase, participants who continued curcumin alone showed sustained stability in clinical scoring tools.
Takeaways
This trial documented statistically significant differences between groups across multiple assessment tools.
Significance
Investigators noted that the formulation’s studied effects may involve activation of the AhR pathway, offering context for future exploration into herbal compounds and gut-related pathways.
Pediatric Gut Discomfort Case Series
A case series conducted at Children’s Hospital Los Angeles and published in Inflammatory Bowel Diseases in 2024 examined CurQD® in eight pediatric participants aged nine to seventeen with ongoing digestive-related challenges, evaluating CurQD® as an adjunct alongside standard care routines.
Results
Within 2.8 to 5.4 weeks:
-
75% showed measurable improvements in assessment tools
-
87.5% demonstrated a predefined measurable response
All participants tolerated the protocol without significant adverse events.
Takeaways
The series described short-term scoring changes and favorable tolerability.
Significance
This study adds to research exploring CurQD® in younger populations within digestive-health contexts.
European Study: Vedolizumab + CurQD® Combination
A European prospective study published in Inflammatory Bowel Diseases in 2025 investigated combined use of Vedolizumab and CurQD® in individuals with active intestinal problems, exploring whether the two approaches could enhance one another’s effects.
Results
Reported observations included:
-
91% showing changes in clinical scoring
-
81% reaching clinician-defined improvement categories
-
36% with endoscopic changes
-
All individuals were steroid-free by week twelve
Takeaways
The study outlined how individuals using both Vedolizumab and CurQD® progressed across assessment tools, endoscopic evaluations, and biochemical markers.
Significance
The investigation added early observations about how natural formulations may be evaluated when used concurrently in research exploring integrative approaches.
Pediatric Safety Study on CurQD®
A prospective, open-label study published in Inflammatory Bowel Diseases in 2025, conducted at Rabin Medical Center, evaluated CurQD® over a period of six weeks, documenting tolerability and patterns in participant assessments.
Results
The publication described stable tolerability and changes in scoring categories observed across the six-week period.
Takeaways
Researchers noted favorable tolerability and measurement patterns consistent with earlier publications.
Significance
The study added pediatric-focused safety observations relevant to ongoing digestive-health research.
CurQD® Long-Term Use: Case Report
A case report published in Case Reports in Gastroenterology in 2025 described the first documented case of full gut improvement achieved using CurQD® in a individual with gut imbalance.
Results
The case report documented changes across follow-up visits, including bowel frequency, reported comfort, and intestinal scoring.
Takeaways
The report described one individual’s long-duration measurement patterns.
Significance
Documented by Dr. Netanel Krugliak and Dr. Mark S. Silverberg at Mount Sinai Hospital in Toronto, this case adds to the literature describing CurQD® as a potential primary plan under specific clinical circumstances.